Conference Day One
Click on a session title for more details
08:50
Opening remarks from the chair
Prof Trevor Jones, Non Executive Director, SIMBEC-ORION GROUP LTD
09:00
In an era of increasingly targeted, personalised and advanced therapies, how must clinical development adapt?
Rajesh Chopra, Vice President of Translational Development, Celgene Corporation
09:30
Attrition in clinical development: the earlier, the better? New approaches to de-risk candidate selection
Orest Hurko, Medical Director, Emd Serono
10:00
Speed networking
10:30
Refreshments
Biomarkers World Day One
10:55Opening remarks from the chair
Dr Jens-Oliver Koopmann, Director, ML Consulting
Biomarkers World Day One
11:00The impact of biomarkers on personalized medicine and clinical practice
Mr Claudio Carini, Global Head Clinical Immunology and Biomarkers, Pfizer
Exploratory Development Day One
11:00Translational aspects of pro-arrythmia risk evaluation: toward the end of Thorough QT studies
Jean-Michel Guillon, Head Of Safety Pharmacology, Sanofi
Biomarkers World Day One
11:30Application of mass spectrometry to the identification, verification and validation of candidate biomarkers and diagnostics
Dr Daniel Chelsky, Chief Scientific Officer, Caprion Proteomics
Exploratory Development Day One
11:30new approaches in safety pharmacology: Can high quality ECG and PK data provide a viable alternative to a thorough QT study?
Ms Corina Dana Dota, Centre Director, AstraZeneca Research and Development Plc
Biomarkers World Day One
12:00Disruptive innovation and emerging technologies - future prospects for biomarkers
Mr Andreas Wallnoefer, Global Head pRED Development, F. Hoffmann - La Roche Ltd
Mr Andreas Schuppert, Director, Bayer
Dr Gereon Lauer, Associate Director, Clinical Biomarkers, Vertex Pharmaceuticals Europe Ltd
Exploratory Development Day One
12:00QT assessment - the new paradigm, but now what?
Dr Joy Olbertz, Senior Director, Cardiovascular Safety Services, Celerion
Biomarkers World Day Two
12:30Linking drug research and clinics - can Big Data be the bridge
Mr Andreas Schuppert, Director, Bayer
Exploratory Development Day Two
12:30Assessing how the new clinical trial regulations will affect early development
Dr Martin O’Kane, Acting Head of the Clinical Trials Unit, MHRA
13:00
Lunch
Interactive roundtables
Biomarkers World Day One
15:30Internal decision-making biomarkers in the clinical development of CRTH2 antagonists
Dr Daniel Strasser, Senior Lab Head, Translational Science, Actelion
Exploratory Development Day One
15:30Overcoming challenges of conducting early phase paediatric clinical trials
Dr Philippe Auby, Vice President of Global Clinical Research, Paediatric Neuro-Psychiatry, Lundbeck
Biomarkers World Day One
16:00Safety and DMPK biomarkers
Dr Gerhard Gross, Scientific Director, Johnson & Johnson
Exploratory Development Day One
16:00Strategies for the successful execution of specialized early development trials: considerations in the recruitment and medical management of special populations
Ms Lorraine Rusch, Vice President of Business Development, Vince and Associates Clinical Research Inc
Biomarkers World Day One
16:30Lessons from IMI SAFE-T Consortium's collaborative biomarker qualification
Dr Thomas Joos, Deputy Managing Director, NMI Natural and Medical Sciences Institute at the University of Tuebingen
Exploratory Development Day One
16:30Translational medicine and early clinical trial design to optimise clinical success
Alberto Martinez, Director TMCP, Daiichi Sankyo
Biomarkers World Day One
17:00How imaging can aid decision making in translational medicine and early development
Dr Heiko Niessen, Team Leader Clinical Imagining, Boehringer Ingelheim
Exploratory Development Day Two
17:00Matchmaking in oncology: challenges and considerations for accelerating early phase drug development of combination therapies
Hazel Jones, Head of Combination Therapies, Cancer Research U.K.
17:30
Closing remarks
Drinks party
last published: 12/Jun/15 16:38
Co-located with Biomarkers World Europe:
